Pre-operative Endocrine Therapy

被引：17

作者：

Arthur L.M. ^{[1
]}

Turnbull A.K. ^{[1
]}

Khan L.R. ^{[2
]}

Dixon J.M. ^{[1
]}

机构：

[1] Edinburgh Breast Cancer Now Research Team, Division of Pathology Laboratories, Institute of Genetics and Molecular Medicine, Western General Hospital, The University of Edinburgh, Crewe Road South, Edinburgh

[2] Edinburgh Breast Unit, Western General Hospital, Crewe Road South, Edinburgh

来源：

Current Breast Cancer Reports | 2017年 / 9卷 / 4期

关键词：

Aromatase inhibitor; Breast cancer; Endocrine therapy; Neoadjuvant; Pre-operative; Tamoxifen;

D O I：

10.1007/s12609-017-0255-6

中图分类号：

学科分类号：

摘要：

Purpose of Review: Pre-operative endocrine therapy can be used to down-stage large or locally advanced breast cancers in ER+ disease. In the last four decades, it has evolved from a treatment perceived as an alternative to surgery for those too unfit to undergo surgery or chemotherapy, to the present day where it is a valuable and valid option in the treatment of postmenopausal women with ER-rich (Allred score 7–8, or > 50% staining for ER) breast cancer. Recent Findings: Emerging data from the metastatic setting is translating into neoadjuvant trials, utilising dual endocrine targeting or combinations of endocrine agents and other targeted drugs, including those acting against components of the PI3K pathway and the cell cycle. The routine use of peri-operative endocrine therapy in all ER+ tumours may help to yield important long-term prognostic information, and guide adjuvant endocrine therapy. Summary: Pre-operative endocrine therapy is an exciting and evolving area with emerging new approaches. In this review, established evidence and emerging data on its applications are discussed. © 2017, The Author(s).

引用

页码：202 / 209

页数：7

共 53 条

[1]

Perloff M., Lesnick G.J., Chemotherapy before and after mastectomy in stage III breast cancer, Arch Surg, 117, 7, pp. 879-881, (1982)

[2]

Fisher B., Et al., Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18, J Clin Oncol, 15, 7, pp. 2483-2493, (1997)

[3]

Dixon J.M., Role of endocrine therapy in the neoadjuvant surgical setting, Ann Surg Oncol, 11, pp. 18S-23S, (2004)

[4]

Macaskill E.J., Dixon J.M., Neoadjuvant use of endocrine therapy in breast cancer, Breast J, 13, 3, pp. 243-250, (2007)

[5]

von Minckwitz G., Et al., Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J Clin Oncol: Off J Am Soc Clin Oncol, 30, 15, pp. 1796-1804, (2012)

[6]

Cance W.G., Et al., Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival, Ann Surg, 236, 3, pp. 295-302, (2002)

[7]

Makris A., Et al., A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer, Ann Oncol, 9, 11, pp. 1179-1184, (1998)

[8]

Semiglazov V.F., Et al., Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer, Cancer, 110, 2, pp. 244-254, (2007)

[9]

Spring L.M., Et al., Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis, JAMA Oncol, 2, 11, pp. 1477-1486, (2016)

[10]

Cortazar P., Et al., Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet, 384, 9938, pp. 164-172, (2014)

← 1 2 3 4 5 6 →